Navigation Links
A New Two-gene Test to Discern Similar Gastrointestinal Cancers

Researchers have devised a powerful two-gene test that can distinguish between a pair of nearly identical gastrointestinal// cancers that require radically different courses of treatment.

Their report is published this week in the online Early Edition of the Proceedings of the National Academy of Sciences.

"This simple and accurate test has the potential to be relatively quickly implemented in the clinic to benefit patients by guiding appropriate treatment," says senior author Wei Zhang, Ph.D., professor in the Department of Pathology at The University of Texas M. D. Anderson Cancer Center.

The analytical technique employed to tell gastrointestinal stromal tumor (GIST) from leiomyosarcoma (LMS) with near perfect accuracy will have wider application in more individualized diagnosis and treatment of other types of cancer, study co-authors from M. D. Anderson and the Institute for Systems Biology in Seattle conclude.

GIST was once thought to be a type of leiomyosarcoma because both originate in the smooth muscle cells of the gastrointestinal tract. However, GIST is treatable with the targeted medication known as Gleevec and is relatively unresponsive to chemotherapy. The opposite is true of LMS. An existing test distinguishes among the two cancers with about 87 percent accuracy, but intensive and time-consuming additional analyses are required for uncertain cases, Zhang says.

The researchers used common whole genome microarrays to measure gene expression in 68 GIST or LMS tumors, but then applied an analytical twist. Rather than identifying multiple genes that might distinguish each type of cancer, the researchers instead analyzed every possible pair of genes, says first author Nathan Price, Ph.D., research scientist at the Institute for Systems Biology, a process called Top Scoring Pair analysis.

The result was a cancer classifier based on the expression ratio of two genes. If the gene OBSCN expr esses more of its RNA than the gene C9orf65, then the tumor is GIST. If C9orf65 is more abundant, it's LMS.

The test accurately identified 67 of the 68 microarrayed tumors, with the exception being one tumor with nearly a 50-50 split between the two expressed genes upon which no diagnosis could be made. An additional test using a more accurate measurement procedure on the two genes identified 20 of the original samples (including the sample with near equal gene expression) and 19 independent samples with 100 percent accuracy, the authors report.

Genomic approaches to diagnosing, selecting treatment and determining a cancer patient's prospects of responding to care are beginning to work their way into the clinic, the researchers note. These approaches can rely on dozens of genes as biomarkers.

Top scoring pair analysis allows the use of fewer genes to distinguish between similar cancers or between groups of patients who have one type of cancer yet respond differently based on genetic indicators, the authors note. For example, paired gene analysis may be used to determine which patients benefit from different types of chemotherapy and which patients are at risk of relapse.

Zhang said the research group is using this analytical strategy to identify gene pairs that can predict which GIST patients respond to Gleevec and how other types of cancer respond to treatment as well.

Source-Eurekalert
PRI
'"/>




Related medicine news :

1. Discerning Sour Taste
2. Similar diseases in married couples
3. Stem Cells, Tumor Cells Share Similar Properties: Scope For Treatment and Prevention?
4. Female Twins Have More To Share Than Just The Similarity: Risk Of Early Menopause
5. Why Are Some People More Depressed Than The Rest When Faced With Similar Situations?
6. Sea Urchin Genome Similar To Man And May Cure Diseases
7. Older Men Have Similar Refracture Risk as Women
8. Newer Class of Antidepressants Similar in Effectiveness, Side Effects Differ
9. Men too Experience Hot Flashes Similar to Women
10. Bypass Surgery, Drug-eluting Stents Possess Similar Risk and Outcome
11. Gastrointestinal ills more common in diabetics
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/17/2017)... CA (PRWEB) , ... January 17, 2017 , ... Livionex, ... the results of a double blind clinical study for its dental gel that shows ... leading national brand of toothpaste containing triclosan. The study was conducted at the Beckman ...
(Date:1/17/2017)... , ... January 17, 2017 , ... ... from two offices in Tyler, has announced the latest beneficiary of their thriving ... Network, a nonprofit organization dedicated to fulfilling the dreams of terminally ill patients. ...
(Date:1/17/2017)... , ... January 17, 2017 , ... Today, FloSports ... Wrestling announced a new agreement as part of a long-term extension of their ... and includes the airing of some of the sport’s premier events exclusively on FloWrestling.com ...
(Date:1/16/2017)... ... January 17, 2017 , ... Recently, patients and staff ... Michigan, joined other volunteers and organizations in support of the annual Binder Park Zoo ... families dressed up in colorful costumes of all designs coming out to enjoy games, ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... products, will demonstrate their groundbreaking GunSport•PRO® and EB15•LE® electronic earplugs at the NSSF ... in Las Vegas, Booth #2809. The SHOT Show is the shooting, hunting and ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Jan. 17, 2017 Following an initial ... praised the Food and Drug Administration,s (FDA,s) final ... Drug Products by Pharmacies and Outsourcing Facilities." In ... limitation on pre-packaging -- which would have put ... to long term care (LTC) pharmacies.  ...
(Date:1/17/2017)... January 17, 2017 ReportsnReports.com adds "Anaphylaxis ... provides an overview of the Anaphylaxis,s therapeutic pipeline with comprehensive ... analysis at various stages, therapeutics assessment by drug target, mechanism ... along with latest updates, and featured news and press releases. ... Complete ...
(Date:1/17/2017)... Jan 17, 2017 Research and Markets has ... Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, ... Forecast to 2021" report to their offering. ... The global active pharmaceutical ingredients ... USD 157.95 Billion in 2016, growing at a CAGR of 6.3% ...
Breaking Medicine Technology: